GarrodA. The inborn factors in disease. Southern Medical Journal, 24, (1931).
2.
EhmannF.et al.Pharmacogenomic information in drug labels: European Medicines Agency perspective. The Pharmacogenomics Journal, 15, (2015).
3.
RellingM. v & KleinT. E.CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clinical Pharmacology & Therapeutics, 89, (2011).
4.
van der LeeM., KriekM., GuchelaarH.-J. & SwenJ. J.Technologies for Pharmacogenomics: A Review. Genes, 11, (2020).
5.
RellingM. v. & EvansW. E.Pharmacogenomics in the clinic. Nature, 526, (2015).
6.
KrebsK. & MilaniL.Translating pharmacogenomics into clinical decisions: do not let the perfect be the enemy of the good. Human Genomics, 13, (2019).
7.
van der WoudenC. H.et al.A brighter future for the implementation of pharmacogenomic testing. European Journal of Human Genetics, 24, (2016).
8.
Qing-pingS.et al.Consequences, measurement, and evaluation of the costs associated with adverse drug reactions among hospitalized patients in China. BMC Health Services Research, 14, (2014).
9.
PlumptonC. O., RobertsD., PirmohamedM. & HughesD. A.A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions. PharmacoEconomics, 34, (2016).
10.
FormicaD.et al.The economic burden of preventable adverse drug reactions: a systematic review of observational studies. Expert Opinion on Drug Safety, 17, (2018).
11.
ChanS. L.et al.Economic burden of adverse drug reactions and potential for pharmacogenomic testing in Singaporean adults. The Pharmacogenomics Journal, 19, (2019).
